Deprescribing after DBS in Dystonia: Promise, Pitfalls, and a Path Forward
Movement Disorders Clinical Practice · 2026-07 · 13 (7) · 1793-1794
DOI: 10.1002/mdc3.70406 ↗Kurz gefasst
Leserbrief in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 11.03.2026. Verfasst von Zunqiang Zhao und 2 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Lanzhou University, Lanzhou, China. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Gansu Province Key Talent Project, Gansu Joint Scientific Research Fund Major Project, National Natural Science Foundation of China.
Abstract (Originalsprache)
This timely study adds useful real-world evidence that deep brain stimulation (DBS) may simplify dystonia care by lowering anti-cholinergic (AchD) exposure and reducing botulinum neuro-toxin (BoNT) use across pediatric and adult cohorts. 1 While the fi ndings are promising, several limitations and future directions merit discussion.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical Medical College of Lanzhou University, Lanzhou, China.
- School of Information Science & Engineering, Lanzhou University, Lanzhou, China.
- Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, China.
- NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, China.
ORCID-Profile: Hui Cai
Förderung
- Gansu Province Key Talent Project
- Gansu Joint Scientific Research Fund Major Project
- National Natural Science Foundation of China
- Gansu Provincial Health Industry Science and Technology Innovation Major Project
- the 2025 Central-Guided Local Science and Technology Development Found
- Natural Science Foundation of Gansu Province
- Gansu Province Health Industry Research Project
- In-House Scientific Research Project of Gansu Provincial Hospita
Zitieren
APA
Zhao, Z., Zhao, S., & Cai, H. (2026). Deprescribing after DBS in Dystonia: Promise, Pitfalls, and a Path Forward. Movement Disorders Clinical Practice, 13(7), 1793-1794. https://doi.org/10.1002/mdc3.70406
Vancouver
Zhao Z, Zhao S, Cai H. Deprescribing after DBS in Dystonia: Promise, Pitfalls, and a Path Forward. Movement Disorders Clinical Practice. 2026;13(7):1793-1794. doi:10.1002/mdc3.70406
BibTeX
@article{Zhao2026,
author = {Zhao, Zunqiang and Zhao, Sihan and Cai, Hui},
title = {Deprescribing after DBS in Dystonia: Promise, Pitfalls, and a Path Forward},
journal = {Movement Disorders Clinical Practice},
year = {2026},
volume = {13},
number = {7},
pages = {1793--1794},
doi = {10.1002/mdc3.70406}
}
EUVIMED